Literature DB >> 29433355

What would be missed in the first trimester if nuchal translucency measurement is replaced by cell free DNA foetal aneuploidy screening?

Lv-Yin Huang1, Min Pan1, Jin Han1, Li Zhen1, Xin Yang1, Dong-Zhi Li1.   

Abstract

The aim of this study was to evaluate which chromosomal abnormalities in our cohort of foetuses with increased nuchal translucency (NT) in the first trimester of pregnancy could be detected by cell free (cf)DNA screening as well. There were 775 singleton pregnancies referred for cytogenetic testing due to an increased NT (≥3.0 mm). Chromosome aberrations were investigated using karyotyping or chromosomal microarray analysis (CMA). Karyotyping had been chosen for foetal cytogenetic testing by 446 patients, and CMA by 329 patients. Common aneuploidies (trisomies 21, 18, 13 and sex aneuploidies) were detected in 2.2% (99/446) and 1.8% (59/329) cases, respectively. In 329 with CMA testing, clinically significant copy number variations (CNVs) other than common aneuploidies were detected in 2.7% cases; among these, five had a pathogenic microscopic CNV, which could have been detected by karyotyping. There were four cases (1.2%) having a pathogenic submicroscopic CNV, which could have been missed by karyotyping. The total CMA detection rate (23.4%) was not statistically different from that (24.2%) by karyotyping (p > .05). The percentage of chromosomal aberrations, which cfDNA screening would miss in patients with increased NT in the first trimester, might be the same as in those with normal NT. Impact statement What is already known about this topic? First trimester NT is a powerful marker for screening for common aneuploidies. cfDNA screening is more accurate than any standard screening with NT. The need of NT in the era of prenatal screening using cfDNA is debated. What does this study add? An increased NT did not identify any additional aneuploidies that were detected by cfDNA screening. What are the implications of these findings for clinical practice and/or further research? The percentage of chromosomal aberrations which cfDNA screening would miss in patients with increased NT might be the same as in those with normal NT.

Entities:  

Keywords:  Nuchal translucency; cell free DNA screening; chromosomal microarray analysis; prenatal diagnosis; submicroscopic chromosomal abnormalities

Mesh:

Substances:

Year:  2018        PMID: 29433355     DOI: 10.1080/01443615.2017.1391755

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  1 in total

1.  Rare chromosomal abnormalities: Can they be identified using conventional first trimester combined screening methods?

Authors:  Daniel Kane; Mary E D'Alton; Fergal D Malone
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2021-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.